Abstract:Purpose Fatty acid binding protein 4 (FABP4) has been demonstrated to be secreted from adipocytes in an unconventional pathway associated with lipolysis. Circulating FABP4 is elevated in metabolic disorders and has been shown to affect various peripheral cells such as pancreatic β-cells, hepatocytes and macrophages, but its effects on adipocytes remains unclear. The aim of this study was to investigate the effects of exogenous FABP4 (eFABP4) on adipocyte differentiation and function. Methods 3T3-L1 pre-adipocytes or mature adipocytes were treated with recombinant FABP4 in the absence or presence of FABP4 inhibitor I-9/p38 MAPK inhibitor SB203580; Meanwhile male C57BL/6J mice were subcutaneously injected twice a day with recombinant FABP4 (0.35 mg/kg) with or without I-9 (50 mg/kg) for 2 weeks. The effects of eFABP4 on differentiation, lipolysis and inflammation were determined by triglyceride measurement or lipolysis assay, western blotting, or RT-qPCR analysis. Results eFABP4 treatment significantly reduced intracellular triglyceride content and decreased expression of adipogenic markers peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT/enhancer binding protein alpha (C/EBPα), intracellular FABP4, and adiponectin in 3T3-L1 cells. Besides, eFABP4 promoted lipolysis and inflammation in differentiated 3T3-L1 adipocytes as well as in adipose tissue of eFABP4-treated C57BL/6J mice, with elevated gene expression of monocyte chemoattractant protein (MCP)-1, tumor necrosis factor (TNF)-α, and elevated protein expression of adipose triglyceride lipase (ATGL), phosphorylation of hormone-sensitive lipase (HSL) (Ser-660), p38, and nuclear factor-kappa B (NF-κB). The pro-inflammatory and pro-lipolytic effects of eFABP4 could be reversed by SB203580/I-9. Conclusions These findings indicate that eFABP4 interferes with adipocyte differentiation, induces p38/HSL mediated lipolysis and p38/NF-κB mediated inflammation in adipocytes in vitro and in vivo.

Identification of New Dual FABP4/5 Inhibitors Based on a Naphthalene-1-sulfonamide FABP4 Inhibitor.

Development of FABP4/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus

Small molecule inhibitors of human adipocyte fatty acid binding protein (FABP4).

From Hit to Lead: Structure-based Discovery of Naphthalene-1-sulfonamide Derivatives As Potent and Selective Inhibitors of Fatty Acid Binding Protein 4.

Optimization of Potent, Selective and Orally Bioavailable Biphenyl Scaffold As FABP4 Inhibitors for Anti-Inflammation.

Structural Insights into Ligand Binding Features of Dual FABP4/5 Inhibitors by Molecular Dynamics Simulations

Novel fatty acid binding protein 4 (FABP4) inhibitors: virtual screening, synthesis and crystal structure determination.

Therapeutic potential of a synthetic FABP4 inhibitor 8g on atherosclerosis in ApoE-deficient mice: the inhibition of lipid accumulation and inflammation

Design, Synthesis and Biological Evaluation of FABP4/5 Inhibitors Based on Quinoline Scaffold

Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors

Analysis of binding affinity and docking of novel fatty acid-binding protein (FABP) ligands

Molecular Dynamics Exploration of Selectivity of Dual Inhibitors 5M7, 65X, and 65Z Toward Fatty Acid Binding Proteins 4 and 5.

The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation

Design, Synthesis, and Biological Evaluation of First-in-class FABP1 Inhibitors for the Treatment of NASH

Molecular Mechanism with Regard to the Binding Selectivity of Inhibitors Toward FABP5 and FABP7 Explored by Multiple Short Molecular Dynamics Simulations and Free Energy Analyses

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Exogenous FABP4 interferes with differentiation, promotes lipolysis and inflammation in adipocytes

FABP4 inhibitor BMS309403 decreases saturated-fatty-acid-induced endoplasmic reticulum stress-associated inflammation in skeletal muscle by reducing p38 MAPK activation

Design, Synthesis, and Biological Evaluation of Novel Dual FFA1 (gpr40)/pparδ Agonists As Potential Anti-Diabetic Agents.

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.